Concepedia

Linda Rollin

LR

Statistics

Publications

10

Citations

6.7K

H-Index

10

Active since

2006

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Colorado Denver

The Maria Sklodowska-Curie National Research Institute of Oncology

Istituti di Ricovero e Cura a Carattere Scientifico

Dana-Farber Cancer Institute

Linda Rollin is an author at Bristol-Myers Squibb (United States) specializing in pharmacotherapy, oncology, and cancer immunotherapy.

Publications per year

2006–2019

10

Publications

10

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

, , +17

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Célèste Lebbé, Nicolás Meyer, Laurent Mortier et al. · Journal of Clinical Oncology · 2019 · 398 citations · Full text

, , +17

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Vladimir Coric, Christopher H. van Dyck, Stephen Salloway et al. · Archives of Neurology · 2012 · 369 citations

, , +17

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

Gary Sachs, Raymond Sanchez, Ronald N. Marcus et al. · Journal of Psychopharmacology · 2006 · 249 citations

, , +16

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study

Ronald N. Marcus, Arif Khan, Linda Rollin et al. · Bipolar Disorders · 2011 · 130 citations

, , +11

1–5 of 10